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PURPOSE. AAV vectors produce stable transgene expression and
elicit low immune response in many tissues. AAVs have been
the vectors of choice for gene therapy for the eye, in particular
the retina. scAAVs are modified AAVs that bypass the required
second-strand DNA synthesis to achieve transcription of the
transgene. The goal was to investigate the ability of AAV vec-
tors to induce long-term, safe delivery of transgenes to the
trabecular meshwork of living animals.
METHODS. Single doses of AAV2.GFP and AAV2.RGD.GFP/
Ad5.LacZ were injected intracamerally (IC) into rats (n  28
eyes). A single dose of scAAV.GFP was IC-injected into rats (n
 72 eyes) and cynomolgus monkeys (n  3). GFP expression
was evaluated by fluorescence, immunohistochemistry, and
noninvasive gonioscopy. Intraocular pressure (IOP) was mea-
sured with calibrated tonometer (rats) and Goldmann tonom-
eter (monkeys). Differential expression of scAAV-infected hu-
man trabecular meshwork cells (HTM) was determined by
microarrays. Humoral and cell-mediated immune responses
were evaluated by ELISA and peripheral blood proliferation
assays.
RESULTS. No GFP transduction was observed on the anterior
segment tissues of AAV-injected rats up to 27 days after injec-
tion. In contrast, scAAV2 transduced the trabecular meshwork
very efficiently, with a fast onset (4 days). Eyes remained clear
and no adverse effects were observed. Transgene expression
lasted 3.5 months in rats and 2.35 years in monkeys.
CONCLUSIONS. The scAAV viral vector provides prolonged and
safe transduction in the trabecular meshwork of rats and mon-
keys. The stable expression and safe properties of this vector
could facilitate the development of trabecular meshwork drugs
for gene therapy for glaucoma. (Invest Ophthalmol Vis Sci.
2010;51:236–248) DOI:10.1167/iovs.09-3847
The cells of the outflow pathway of the eye are ideal targetsfor gene transfer for many specific reasons. Their location,
morphology, and physiology all seem to be tailored for efficient
gene delivery. First, because of the natural flow of aqueous
humor, genes delivered into the anterior chamber preferen-
tially reach the trabecular meshwork. Second, once the vectors
reach the trabecular meshwork, the physiological flow pattern
of the fluid between and around the trabecular meshwork cell
layers provides the transfer molecules with a longer contact
time and facilitates their entry into the cells. Another advantage
is the spongiform loose structure and optically empty spaces of
the tissue architecture, which allows direct access of the trans-
fer molecules to most cells. Fluid crossing through the inner
wall monolayer of Schlemm’s canal (SC) further permits the
transfer molecules to directly contact the Schlemm’s canal
cells. Finally, the anterior chamber is an immune privileged
site.1 Collectively, these properties offer the opportunity to
alter gene expression in the trabecular meshwork and investi-
gate the contribution of a given gene-encoded mechanism to
the maintenance of aqueous humor outflow resistance. Most
important, gene transfer to the trabecular meshwork would
facilitate efficient development of more precisely targeted and
less toxic drugs for the treatment of glaucoma, a chronic
disease that affects more than 70 million people worldwide.2,3
Several viral vectors have been used to transfer genes to the
trabecular meshwork in living animals. Recombinant E1/E3
adenoviruses transduce the trabecular meshwork tissue very
efficiently. Reports of the use of this viral vector have shown
functional expression in the trabecular meshwork of all ani-
mals studied, from rodents to monkeys.4–8 Although at high
concentrations delivery of adenoviruses can induce an immune
response,7,9 intraocular injections at appropriate concentra-
tions are well tolerated in mice, rats, rabbits, monkeys, and
humans.7,10–14 However, their length of expression is short,
with reported durations of 1 to 3 weeks in most animals,5,7 and
in monkeys, repetitive injections were not always well toler-
ated.7 These properties would make the use of adenoviruses in
glaucoma therapy problematic, given the chronicity of the
disease.7 The transient transgene expression of the adenoviral
vectors has been attributed almost equally to the elimination of
the cells infected with the virus15 and to the silencing of their
cytomegalovirus (CMV) promoter.16 Lentiviral vectors, such as
the feline immunodeficiency virus (FIV) have been shown to
transduce the trabecular meshwork of living cats and monkeys
with reported durations thus far up to 2.3 and 1.25 years,
respectively.17,18 However, the lentiviral vector strain derived
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from the human immunodeficiency virus type 1 using an elon-
gation factor (EF-1) promoter, transduced the trabecular
meshwork of rats for just 3 weeks.19
Because of their stable, long-term expression and their low
immunogenicity, adeno-associated viral vectors (AAV) have
been the vectors of choice for gene therapy for the retina. AAV
vectors are used in most retinal ganglion cell (RGC) survival
studies,20,21 as well as in those involving retinal degeneration
models.22,23 Furthermore, AAV was the vector used in the first
case of restoration of visual function in a dog model of Leber
amaurosis.23 This AAV is currently in phase I gene therapy
clinical trials showing improved vision and no adverse effects
in three young adults with inherited blindness.24 AAVs are
defective parvoviruses that contain a 4.7-kb single-stranded (ss)
DNA flanked by inverted terminal repeats.25,26 They require a
helper adenovirus for infection, and their genome encodes the
AAV proteins needed for replicating and packaging. On enter-
ing the cell, the viral ss DNA is converted into a transcription-
ally active double-stranded DNA by host enzymes.25,26 A re-
combinant AAV vector replaces the DNA encoding both of its
viral proteins by a transgene expression cassette and therefore
does not contain any open viral reading frames. This replace-
ment allows transgene insert sizes of approximately 4.5 kb,
which is an adequate size to accommodate the coding regions
of most of the polymerase II genes. AAV vectors infect and
transfer genes to dividing and nondividing cells, and methods
have been developed to easily grow them to high titers without
the need of the helper adenovirus.27,28 In a good number of
animal models and clinical trials in which AAV transgene ex-
pression lasted for a long time (5 years in primates),29 no
immunologic response to the transgene was found.30 How-
ever, certain combinations of AAV transgenes and target tissues
have induced an immune response.31,32 It is currently thought
that this occasional response depends on several factors such
as the nature of the transgene, the promoter used, the route
and site of administration, the vector dose, and host fac-
tors.30,32,33 Altogether, the attractive features offered by AAV
vectors have made them among the most widely used in
clinical trials.34
However, AAV vectors are unable to transduce trabecular
meshwork cells.8,35 Our laboratory has recently shown that the
lack of transduction of AAV to these cells was not due to a
failure of viral entry but rather to an inability of the host cells
to convert the viral ss DNA to double stranded.36 In the same
study, we showed that the trabecular meshwork (cells and
organ cultured tissue) could be efficiently transduced by the
new generation self-complementary AAV (scAAV),37,38 which
bypasses the required second-strand DNA synthesis to achieve
the transcriptionally active AAV genome. The recombinant
scAAV DNA contains one mutated and one wild-type terminal
repeat flanking the expression cassette. After several AAV rep-
lication forks, this feature allows the generation of an ss viral
genome carrying both sense and complimentary cDNA of the
transgene, separated by the mutated terminal repeat and
flanked by wild-type repeats. On entry into the host, both
strands pair with each other generating the AAV double-
stranded DNA needed for transcription.39 The scAAV expres-
sion cassette’s size is reduced from the original 4.5 to 2.2. kb
which, although smaller, would still allow expression of most
trabecular meshwork candidate genes (cDNA of approximately
1500 bp).40,41
In the present study, we extended our investigations with
scAAV from in vitro experiments to living animals. We report
that a single intracameral injection of an scAAV viral vector
confers stable long-term expression of a reporter gene in the
trabecular meshwork of living rats (3.5 months) and mon-
keys (2 years) with an early onset and a safe clinical profile.
METHODS
Experimental Animals
All animal procedures were approved by the Institutional Animal Care
and Use Committee at the University of North Carolina (UNC) and the
University of Wisconsin (UW) and were conducted in accordance with
the tenets of the Declaration of Helsinki and the ARVO Statement for
the Use of Animals in Ophthalmic and Vision Research. Rat strains
were either male Brown Norway (300–400 g) retired breeders or male
Wistar (200–300 g) and were purchased from Charles River Laborato-
ries (Wilmington, MA). All animals were housed in standard 12-hour
cycle lighting with food and water provided ad libitum. Twenty ani-
mals were used for the AAV2 study (all Brown Norway) and 53 animals
were used for the scAAV2 study (10 Brown Norway and 43 Wistar).
One group of six rats was excluded from the analysis because of
technical problems.
Three male and three female cynomolgus macaques (Macaca fas-
cicularis), 8 to 17 years of age, weighing 5.8 to 6.8 kg, acquired from
Covance (Vienna, VA) and Pfizer Laboratories (New York, NY), were
used in the study. All monkeys were housed in standard 12-hour cycle
lighting with water provided ad libitum and food, twice daily. A
detailed enrichment program was used that included social housing,
toys and other objects to manipulate, cage furniture, foraging devices,
a small manipulable mirror, fruit, and other nutritive snacks, radio, and
TV and movies.
Viral Vectors
Recombinant adeno-associated vectors—AAV2.GFP, AAV2.RGD.GFP,
and scAAV2.GFP—contained the enhanced GFP gene driven by human
enhanced cytomegalovirus (CMV) promoter. They were all prepared
by triple-transfection of 293 cells at the University of North Carolina
Virus Vector Core, as previously described.42,43 The viruses were
purified by the use of non-ionic iodixanol gradients followed by hep-
arin-affinity chromatography with HPLC columns. Plasmids for the
production of AAV2.GFP were pTRUFR, which encodes the GFP ex-
pression cassette packaged between the AAV2 terminal repeats; pXX2,
which encodes the rep and cap genes; and pXX6–80, which encodes
the adenoviral helper function genes.42 The rep and cap plasmid for
AAV2.RGD.GFP (whose capsid contains an RGD peptide) was
pA5884C-RGD.44 The GFP expression cassette was also cloned into the
scAAV2 vector construct, with the mutated end of the inverted termi-
nal repeat (ITR) next to the promoter of the gene expression cas-
sette.37,38 Vector physical particles were assessed by dot blot.
The Ad5.LacZ adenovirus used in the combination injections was
purchased from Qbiogen (Montreal, Quebec, Canada) and contains the
-galactosidase gene under the control of the CMV promoter. The virus
was grown and purified in our laboratory as described.45 Virus particle
number was determined by measurement of their optical density at
260 nm using the formula 1 g DNA (2.2  1010 viral particles [VP]).
The vector AAV2CBA.GFP46 was generously provided by Thomas J.
McCown (Gene Therapy Center, University of North Carolina).
Intraocular Administration of Recombinant
Viral Vectors
Each rat was anesthetized by intraperitoneal injection of 1 mL/kg of a
standard rat cocktail consisting of a solution of 5 mL ketamine (100
mg/mL), 2.5 mL xylazine (20 mg/mL), 1 mL acepromazine (10 mg/mL),
and 1.5 mL of water. While resting on its side, the rat was placed under
a surgical microscope with the head propped up in a holder and eyes
directed upward. The corneas were anesthetized with 1 drop of 0.5%
proparacaine hydrochloride (Alcaine; Alcon, Fort Worth, TX). For the
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intracameral vector delivery, a 30-gauge needle was inserted through
the cornea at the limbus with the bevel up to gently reach the center
of the anterior chamber (AC). The needle device consisted of the tip of
a 30-gauge needle, broken at the middle, connected to one end of
intramedic-polyethylene tubing (PE-10; Clay Adams, Parsippany, NJ).
The remaining half of the needle, plus the hub, was attached at the
other end of the tubing and then connected to a dispenser (Gilmont
Micrometer; Barnant, Barrington, IL). The tubing was partially filled
with a colored glycerol driving solution to allow aspiration of 3 to 5 L
of the viral sample. Inside the tubing, the driving solution was kept
separated by 3 to 4 cm from the sample at all times. When the needle
was inside the AC, the sample was delivered by the assistant over 30
seconds and fluid entry monitored by direct visualization through the
operating microscope. The needle was left in place for 1 to 2 minutes
and withdrawn gradually to minimize leaking. Topical antibiotic oint-
ment (neomycin 3.5 mg/g, polymyxin B 10,000 U/g, and bacitracin 400
U/g; Akorn, Lake Forest, IL) was placed on the eyes, and the animals
were returned to their cages, resting on absorbent paper for recovery.
The rats’ eyes were enucleated immediately after euthanatization
and immersed in fresh 4% paraformaldehyde in PBS for 30 minutes.
The eyes were then opened at the equator, the lens removed, and
wedge shape specimens containing the anterior chamber angle region
with the trabecular meshwork fixed for an additional hour. Specimens
were then consecutively washed in 10% sucrose (6 hours) and 30%
sucrose (overnight) and frozen in OCT (Tissue-Tek; Sakura Finetek,
Torrance, CA) in liquid nitrogen. Meridional 10-m sections were
mounted on microscope slides (Superfrost/Premium; Thermo Fisher,
Waltham, MA, with Fluoromont G; Southern Biotechnology Associates,
Birmingham, AL) and GFP was visualized with a fluorescence micro-
scope (model IX71; Olympus, Tokyo, Japan). Images were captured
with a digital camera (DP70; Olympus) and accompanying software.
Digital images were arranged with image-analysis software (Photoshop
CS; Adobe Photoshop, Mountain View, CA).
Specimens from monkey 3 and perfused monkey anterior segments
were shipped to UNC in a container with a small amount of saline,
packed in ice and processed, fixed, and analyzed as just described. For
immunohistochemistry, 10-m frozen sections were blocked with 10%
goat serum in PBS for 30 minutes followed by overnight incubation
with Alexa Fluor 594-conjugated anti-GFP monoclonal antibody (In-
vitrogen, Carlsbad, CA), 1:1000 diluted in 10% goat serum, and 0.3%
Tween in PBS. The washing buffer was PBS (three times, 10 minutes
each). The sections were then mounted and analyzed as described for
fluorescence histochemistry.
For vector administration, the monkeys were anesthetized (ket-
amine HCl, 10 mg/kg, supplemented with 5 mg/kg, and medetomidine
15–75 g/kg), and a 30-L bolus, 3  1010 VP, of scAAV2.GFP vector
preparation was injected transcorneally, in 15-L increments, into the
anterior chamber. Vector solutions were injected with a 30-gauge
needle connected to a micrometer syringe with polyethylene (PE 10)
tubing. Under microscopic visualization, the needle was threaded
through the cornea for several millimeters, and the tip angled into the
anterior chamber. The needle was left in place for 2 minutes after
vector injection to allow for tubing hysteresis to subside. No fluid
leakage was observed during needle withdrawal.
Gonioscopy and Goniophotography
The monkeys were regularly examined with a slit lamp biomicroscope
for corneal and lenticular clarity and for evidence of anterior chamber
cells and flare. GFP expression was monitored serially and noninva-
sively as previously described.7 Briefly, a drop of 0.5% proparacaine
hydrochloride was instilled, and a Swan-Jacob gonioscopy lens was
placed on the corneal surface of ketamine-anesthetized (10 mg/kg,
intramuscular initial, supplemented with 5 mg/kg, as needed), supine
monkeys, to view the structures in and adjacent to the iridocorneal
angle. A retinal camera (50EX; Topcon, Tokyo, Japan), fitted with a
digital SLR camera body (D1X; Nikon) and the standard clinical fluo-
rescein exciter and barrier filters, was used to photograph the angle. A
customized microscope (Nikon Instruments, Inc., Melville, NY) with a
12-bit, monochromatic, cooled-CCD camera (Retiga 2000RV; Q-Imag-
ing Burnaby, BC, Canada) and a specific GFP filter set was also used to
collect images of the angle at several time points. Another imaging
configuration used to collect color images of the angle combined the
digital camera with a 175-W xenon nova light source and a 3-mm 
6-cm 0° tele-otoscope probe (Hopkins II; Karl Storz Endoscopy-Amer-
ica, Inc., Culver City, CA). A drop of 0.5% proparacaine hydrochloride
was placed on the cornea, and 2.5% hydroxypropyl methylcellulose
was used as an interface between the tip of the probe and the cornea.
Measurement of Rat and Monkey
Intraocular Pressure
Intraocular pressures (IOP) were recorded in sedated rats once or
twice a week. At the beginning of the study, IOPs were recorded with
a calibrated handheld tonometer (Tonopen XL; Mentor, Norwell, MA)
and midway through the study, IOPs were measured by the use of the
rebound tonometer.47 The tonometer was calibrated by inserting a
needle into the anterior chamber of anesthetized rats and connecting
it to a column of water. The rebound tonometer instrument used was
one of the prototypes developed at Mount Sinai School of Medicine
(New York) and was generously provided to us by Thomas Mittag and
John Danias.47,48 The rats were lightly anesthetized with the described
intraperitoneal ketamine/xylazine/acepromazine cocktail at half dose
and with an eye drop of 0.5% proparacaine. To take IOP measure-
ments, the rats were positioned with the visual axis horizontal to the
probes. For the tonometer, IOPs were obtained as the average of 10
consecutive measurements for each eye. For the rebound tonometer,
the probe was held at a distance between 2 and 5 mm and five
consecutive readings (arbitrary units that correlate to IOP) were ob-
tained by pressing the foot pedal connected to the probe power
supply. Only mean values with a standard deviation (expressed as
percentage of the mean) less than 5% were accepted. The rebound
tonometer was calibrated on rats at the same ages as those used in the
experiments (before and 3.5 months after injection) by ex vivo can-
nulation and manometric readings as described.47 IOP-correlated val-
ues were obtained by creating a logarithmic calibration curve with the
tonometer and manometric values and obtaining the a and b constant
values in the calibration curve formula [Y  aLn(X)  b], where X is
the correlated IOP and Y is the tonometer’s measurement. The corre-
lated IOP (X)  [exponent(tonometer value  b)/a)]. The calibration
curves had correlation coefficients of 0.98 and 0.96, respectively.
Monkey IOP was measured with a minified Goldmann tonometer in
ketamine anesthetized (10 mg/kg, intramuscular initial, supplemented
with 5 mg/kg, as needed), supine monkeys.49 Nondairy creamer was
used as a tear film interface instead of fluorescein (which could poten-
tially confound the subsequent examinations) to determine presence
and location of the GFP marker. Measurements were taken every 3 to
4 days for the first 2 weeks, weekly for 4 to 6 weeks, then every 2 to
4 weeks. IOP measurements were usually performed before and on the
same day as slit lamp biomicroscopy and goniophotography, to mini-
mize exposure to anesthesia.
Outflow Facility Cells
To generate primary human trabecular meshwork (HTM) cells, the
trabecular meshwork was dissected from a residual cornea rim after
surgical corneal transplantation at the UNC eye clinic. Specimens were
cut in small pieces, carefully attached to the bottom of a 2% gelatin-
coated 35-mm dish, and covered with a drop of medium (improved
minimal essential medium [IMEM], 20% fetal bovine serum [FBS], 50
g/mL gentamicin) and a coverslip. Dishes were incubated in a hu-
midified 6% CO2 atmosphere, medium was changed every other day,
and the cells were allowed to grow from the explant for a period of 4
weeks. Once confluent, the cells were passed to a T-25 flask and
labeled as passage 1. Subsequently, cells were passed 1:4 to confluence
and maintained in the same medium with 10% FBS. All cells were used
at passages 4 to 6. These outflow pathway cultures include the cells
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from the three distinct regions of the trabecular meshwork plus cells
lining the SC. Because most of the cells in these cultures come from the
trabecular meshwork, they are commonly referred to as trabecular
meshwork cells. The cells used in this study were from a 29-year-old
donor (HTM-63).
RNA Extraction and Hybridization to
Gene Microarrays
The primary human trabecular cell line HTM-63 was grown to 80%
confluence and infected with scAAV2.GFP (1400 VP/cell). Total RNA
from 10-cm plates infected and uninfected dishes was extracted 5 days
after infection. Cellular pellets were resuspended in guanidine thiocy-
anate buffer (RLT; Qiagen, Chatsworth, CA) and loaded onto a column
(QIAshredder; Qiagen), and the extraction was continued (RNeasy
Mini kit with on-column RNase-free DNase digestion; Qiagen), accord-
ing to the manufacturer’s directions. Total RNA recoveries averaged 30
g per plate.
The RNAs were prepared for hybridization to human genome
microarrays (U133A GeneChips, n  2; Affymetrix, Santa Clara CA) at
the UNC Functional Genomics Core Facility. Seven micrograms of total
RNA was used to synthesize cDNA. A custom cDNA kit from Life
Technologies (Gaithersburg, MD) was used with a T7-(dT)24 primer for
this reaction. Biotinylated cRNA was then generated from the cDNA
reaction (BioArray High Yield RNA Transcript Kit; Enzo Life Sciences,
Farmingdale, NY). The cRNA was then fragmented in fragmentation
buffer (5 fragmentation buffer: 200 mM Tris-acetate [pH 8.1], 500
mM KOAc, and 150 mM MgOAc) at 94°C for 35 minutes before the
chip hybridization. Fifteen micrograms of fragmented cRNA was then
added to a hybridization cocktail (0.05 g/L fragmented cRNA, 50 pM
control oligonucleotide B2, BioB, BioC, BioD, and cre hybridization
controls, 0.1 mg/mL herring sperm DNA, 0.5 mg/mL acetylated BSA,
100 mM MES, 1 M [Na], 20 mM EDTA, and 0.01% Tween 20). Ten
micrograms of cRNA was used for hybridization. Arrays were hybrid-
ized for 16 hours at 45°C (GeneChip Hybridization Oven 640; Af-
fymetrix). The arrays were washed and stained with R-phycoerythrin
streptavidin (GeneChip Fluidics Station 400; Affymetrix). After this, the
arrays were scanned (GeneArray Scanner; Hewlett Packard). Microar-
ray software (xGeneChip Microarray Suite 5.0; Affymetrix) was used
for washing, scanning, and basic analysis. Sample quality was assessed
by examination of 3 to 5 intensity ratios of certain genes.
A different primary cell line HTM-109 was infected with a lower
number of scAAV2.GFP VP (140 VP/cell) and RNA extracted at 5 days
after infection. RNAs were hybridized to a second set of microarrays (n
 2; Human Genome U133A GeneChip; Affymetrix), treated, and
analyzed as just described.
Reverse Transcription and Real-Time PCR
Reverse transcription (RT) reactions were conducted with 1 g of
HTM cells spectrophotometrically measured, total RNA in a 25-L total
volume of proprietary RT buffer containing random primers, dNTPs,
and 62.5 U of enzyme with RNase inhibitor (Multiscribe MuLV RT;
High Capacity cDNA kit; ABI), according to the manufacturer’s recom-
mendations (25°C for 10 minutes, 37°C for 2 hours).
Fluorescently labeled probes/primers sets were used for selected
genes (TaqMan Gene Expression collection; ABI). The Matrix Gla
probe (MGP) corresponded to sequences from exons 1 and 2
(Hs00179899_m1), the osteoglycin (OGN) probed corresponded to
sequences from exons 3 and 4 (Hs00247901_m1), the secretogranin
(SCG2) probe corresponded to sequences from exons 1 and 2
(Hs00185761_m1), and the 18S RNA probe corresponded to se-
quences surrounding position nucleotide 609 (Hs99999901_s1). Reac-
tions were performed in 20-L aliquots with master mix (TaqMan
Universal PCR; no AmpErase UNG; ABI), run on a real-time PCR system
(model 7500; ABI) and analyzed (7500 System SDS software; ABI).
Relative quantification (RQ) values between treated and untreated
samples were calculated by the formula 2CT, where CT is the cycle
at threshold (automatic measurement), CT is CT of the assayed gene
minus CT of the endogenous control (18S), and CT is the CT of the
normalized assayed gene in the treated sample minus the CT of the
same gene in the untreated sample (calibrator). Because of the high
abundance of the 18S rRNA used as endogenous control and to get a
linear amplification, RT reactions from control and experimental sam-
ples were diluted 104 times before their hybridization of the 18S probe
(TaqMan; ABI). Relative quantifications 1 corresponded to increased
changes (x-fold). Relative quantifications 	1 corresponded to a frac-
tion of the gene expression and were converted to decreased changes
by the formula 1/2CT. That is, an RQ of 4 corresponded to an
increased expression of fourfold (4), whereas an RQ of 0.25 corre-
sponds to a reduction in expression of fourfold (4).
Microarray Expression Analyses
Raw data CEL files from Affymetrix were imported into expression
analysis software (GeneSpring GX, ver. 7.3.1; Agilent Technologies,
Santa Clara, CA). For analysis of expression changes between the
infected and uninfected samples, files were preprocessed with the
Robust Multichip Average (RMA) and normalized using the Data-Trans-
formation and 50th Percentile normalization algorithms. The data-
transformation normalization sets any measurements less than a spec-
ified cutoff value (default 0.01) to the cutoff value; it ensures that no
negative values are loaded. The 50th percentile normalization step
divides the expression values of each chip by the median of all expres-
sion values; it ensures that the expression values for each chip can be
compared. The normalized data were subsequently filtered on expres-
sion level with a minimum signal value of 50 to eliminate genes
expressed at lower levels in at least one of two conditions. To identify
the top changers in expression, we subsequently filtered data on
change, and genes that exhibited at least a twofold increase or de-
crease in the scAAV2.GFP-infected cells were selected. Gene lists, gene
symbols, heat maps, and overlapping Venn diagrams were obtained by
the use of the expression analysis software. Likewise gene ontologies
(GOs) were obtained from the biological processes lists (GO SLIMS;
Affymetrix) available in the software, which contain subsets of the
terms in the whole GO.
Immune Response
Enzyme-Linked Immunosorbent Assay. Sera were ob-
tained by tail vein puncture (rats) and from the femoral vein (monkeys)
and stored at 80°C. The samples were analyzed for antibodies to viral
capsid proteins and the transgenic protein GFP. High-protein binding
ELISA plates (Nunc, Rochester, NY) were coated overnight at 4°C with
109 viral particles (VP)/well and 0.25–0.50-g/well GFP in 100 L 0.1
M sodium carbonate buffer (pH 9.6). The wells were then washed with
PBS containing 0.1% Tween, and blocked with 10% FBS-01% Tween in
PBS for 30 minutes at 37°C. After additional washes, the samples were
incubated with serum dilutions for 2 hours at 37°C. PBS was used as a
negative control. A rabbit anti-AAV2 capsid protein (1:100; U.S. Bio-
logicals, Swampscott, MA) and a mouse monoclonal anti-GFP (1:100;
Chemicon, Billerica, MA) served as positive controls. The wells were
then washed and incubated with 1:1000 diluted horseradish peroxi-
dase–conjugated goat anti-rabbit (controls; Pierce Thermo Scientific,
Rockford, IL) and goat anti-rat or goat anti-monkey (Pierce Thermo
Scientific) for 1 hour in the presence of 3% goat serum. The wells were
washed again, and the color developed (ABTS Peroxidase Substrate;
KPL, Gaithersburg, MD). The plates were read at an optical density of
405 nm in a microplate reader (FLUOstar Optima; BMG LabTechnolo-
gies, Durham, NC). Samples were run in duplicate or triplicate and the
results expressed as the mean 
 SEM. Comparisons between the two
groups were analyzed by the Student’s t-test.
Proliferation Assay. Peripheral blood mononuclear cell
(PBMC) proliferation assays were performed to detect antigen-specific
proliferative responses against the GFP antigen. PBMC were separated
from heparinized venous blood 22 hours after venipuncture by using
single-density gradient (Ficoll; GE Healthcare, Piscataway, NJ).50
Briefly, 5 mL of blood was mixed with 3 mL of PBS and carefully laid
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on top of 6 mL of gradient in a 15-mL tube. Red blood cells were
pelleted by centrifugation at 1500g for 30 minutes, and the PMBCs
were carefully removed from the gradient interface. The PMBCs were
washed twice with PBS and resuspended in 10 mL of RPMI 1640
complete medium supplemented with 10% fetal calf serum, 2 mM
glutamine, and 100 U/mL of penicillin G and streptomycin (Invitro-
gen). Cells (1  105) in 200 L/well were seeded in a 96-well plate and
stimulated with 10 g/well of recombinant GFP (Clontech, Mountain
View, CA). Cells cultured in the absence of GFP were used as a
negative control. Phorbol 12-myristate 13-acetate (PMA) and ionomy-
cin at 10 and 250 ng/mL, respectively (Sigma-Aldrich, St. Louis, MO)
were used as the positive control. Samples were assayed in triplicate.
On day 5, the plates were pulsed with 1 Ci/well of [3H]-thymidine (25
Ci/mmol; Amersham Biosciences, Pittsburgh, PA), and cells were har-
vested after 16 hours. Proliferation ([3H]-thymidine uptake) was as-
sessed by filtration on an automatic cell harvester (ThermoTec, Hutto,
TX) and by reading the incorporated radioactivity (filter) on a scintil-
lation plate reader (Wallac MicroBeta Trilux; PerkinElmer, Waltham,
MA). The stimulation index (SI) was calculated by dividing the mean
counts per minute of [3H]-thymidine incorporated in the GFP-stimu-
lated cells by counts per minute in an unstimulated cell. GFP-specific
proliferative response was defined by a SI  2.
RESULTS
scAAV Overrides Lack of Transduction in the
Trabecular Meshwork of Living Rats
In vitro, enhancement of AAV transduction has been shown to
occur by co-infecting cultured cells with AAV and wild-type
adenoviruses, or AAV with adenovirus capsids alone.51 Our
laboratory also demonstrated that AAV transduction of primary
HTM cells is greatly enhanced by co-infecting AAV2 with all
recombinant adenoviruses tried.36 However, Brown Norway
and Wistar rats injected intracamerally (IC) with 2  1010 to
3  1011 VP of AAV2.GFP or AAV2.GFP/Ad5.LacZ combination
(40:1) or AAV2.RGD.GFP/Ad5.LacZ showed no GFP transduc-
tion on any of the anterior segment tissues at time points from
1 week to 27 days after injection (n  28 eyes). One of the eyes
injected with the enhancement combination36 showed a few
green cells in the iris and TM. The same number of particles of
an AAV2CBA.GFP injected intravitreally (n  4 eyes) showed
intense transduction of the retinal ganglion cells and optic
nerve at 2 weeks (not shown).
Because of our previous results showing scAAV2.GFP trans-
duction in HTM cells and perfused human organ cultures,36 we
tested the efficiency of this vector in living animals. Brown
Norway and Wistar rat eyes injected IC with 3 to 6  109 VP
scAAV2.GFP showed positive fluorescence in most tissues of
the anterior chamber and in particular, the trabecular mesh-
work (n  72 eyes; Fig. 1). Fluorescence appeared as soon as
4 to 9 days after injection in the iris (n  15, 14 positive), and
showed strong positive trabecular meshwork fluorescence at 2
(n  4), 5 (n  15, 10 positive), and 7 to 9 (n  19, 18
positive) weeks and at 2.5 (n  6, 5 positive) and 3 to 3.5
months (n  13, 5 positive), the last time point. Expression of
the GFP driven by the CMV promoter in this viral serotype was
directed to the iris, corneal endothelium, ciliary body, ciliary
muscle, and especially the layers of the trabecular meshwork
including the inner wall of Schlemm’s canal. Stationary cul-
tures of the anterior segment showed strong transduction in
the trabecular meshwork at 72 hours after infection. No GFP-
positive cells were found in the internal layers of the cornea.
scAAV Induction of Long-Term Transduction of
the Anterior Segment of the Living Monkey Eye
To test whether scAAV transduction of the trabecular mesh-
work would occur in a large animal model with an outflow
pathway more similar to that of humans, we injected a single
dose of 3  1010 VP of scAAV2.GFP into the eyes (monkey 1,
OS; monkey 2, OD) of two cynomolgus monkeys. The con-
tralateral eye was injected with PBS. A bright green fluores-
cence was observed as early as 5 days after injection. The
fluorescence was strongest in the area of the anterior ciliary
muscle and uveal meshwork. By gonioscopy, no difference was
observed on the intensity or distribution of the fluorescence
between the two monkeys, and thus it appears that both
monkeys had the same efficiency of transduction. In monkey 2,
same intensity fluorescence continued to be seen and recorded
photographically at approximately monthly intervals up to 2.3
years after injection (Fig. 2). Fluorescence was still observed
when the manuscript was submitted, and the viral-injected eye
remained clear at all times. In monkey 1, fluorescence faded at
70 days after injection after development of an anterior cham-
ber inflammation at 48 days. Although the inflammation was
resolved satisfactorily after sub-Tenon steroid injection, no GFP
expression was recovered (immune response assessment de-
FIGURE 1. Transduction of scAAV2.
GFP in the anterior segments of IC-
injected rats. Representative frozen
meridional sections, 10-m thick,
from rats’ anterior segments at vari-
ous time points. (A) scAAV2 trans-
duction of the trabecular meshwork
(TM) and iris (I) at 2 weeks after
injection. (B, C) scAAV2 transduc-
tion of a variety of tissues including
the TM, iris, ciliary body (CB), and
corneal endothelium at 2.5 and 3
months after injection. (D) Contralat-
eral eyes were injected with vehicle
which served as a control.
scAAV2.GFP transduced the TM of
living rats efficiently. GFP expression
lasted for at least 3 months (last point
tried). SC, Schlemm’s canal. Original
magnification, 200.
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scribed later). In both positive monkeys, evaluation by gonios-
copy revealed that fluorescence was brightest in the anterior
ciliary muscle, iris processes, and uveal meshwork.
To further assess whether all cell layers of the trabecular
meshwork in monkeys were transduced by scAAV2.GFP, we
performed two additional experiments. In the first one, a third
living monkey was injected at the same dose and killed at 19
days after injection. Anterior segments quadrants were then
processed for immunohistochemistry. In the second experi-
ment, monkey anterior segment organ cultures52 were injected
with 2 to 4  1010 VP, perfused for 7 to 8 days, and similarly
evaluated. Cryosections from both experiments analyzed by
both direct fluorescence and GFP antibody showed positive
transduction to the trabecular meshwork (Figs. 3A, 3B). As had
been observed by in vivo gonioscopy, the sections from the
living monkey showed that this scAAV serotype transduced the
anterior ciliary muscle with high efficiency (Fig. 3A). In the
perfused organ cultures, the trabecular meshwork was also
effectively transduced (Fig. 3B).
Histochemical analyses of all other anterior segment tissues
from the monkey killed at 19 days showed that the scAAV2
virus had a high tropism for the cells of the posterior face of
the iris (Fig. 4). Wholemount as well as histologic sections of
the iris showed bright green fluorescent cells almost exclu-
sively on the posterior face. As observed in the living animal by
gonioscopy and in cryosections at the end of the experiment,
the corneal endothelium appeared highly fluorescently labeled
(Fig. 4).
Clinical Signs in Living Rats and Monkeys
Injected with scAAV2
Table 1 summarizes the clinical observations. Rat eyes injected
with the scAAV2 showed neither opacity nor signs of inflam-
mation at any time during the duration of the experiment and
were undistinguishable from the vehicle-injected eye. The viral
injected eye of monkey 1 was clear until 48 days after injection,
when it developed an anterior segment inflammation that sub-
sequently eliminated the transduced cells (described later).
Monkey 2’s virus-injected eye, in which expression is still
being observed by gonioscopy, showed a clear cornea and no
signs of inflammation. Monkey 3 showed trace cells in the
anterior chamber at day 6, which cleared by day 14; its corneas
remained clear. All the monkeys’ eyes were clear at the end of
the experiment.
Effect of scAAV Transduction on the IOP of Living
Rats and Monkeys
IOPs (mean 
 SE) shown in this section and in Figure 5 were
obtained with a rebound tonometer48 and were derived by
creating a logarithmic calibration curve with the tonometer
and manometric values. Figure 5A shows the results of two rat
experiments (n  8 each). Experiment 1 was conducted over
92 (n  6) and 62 (n  2) days, and experiment 2 over 75 days
(n  8). Figure 5A shows the absolute IOPs for the vehicle and
scAAV injected eyes over time in each animal group. In exper-
iment 1, the IOP averages for the vehicle injected eye were
9.2 
 0.27 mm Hg at baseline and 11.5 
 0.14 mm Hg at 92
days after injection, whereas those of the scAAV2-injected eye
were 9.2 
 0.25 mm Hg at baseline and 11.6 
 0.27 mm Hg at
92 days. In experiment 2, the IOP averages for the vehicle-
injected eye were 10.4 
 0.39 mm Hg at baseline and 11.5 

0.21 mm Hg at 75 days after injection, whereas those of the
scAAV2-injected eye were 10.4 
 0.27 mm Hg at baseline and
11.7 
 0.18 mm Hg at 75 days. The peak IOP (defined as the
highest IOP obtained for each eye at any time during the study
period) averaged 11.3 
 0.2 mm Hg for the vehicle-injected
(control) eyes and 11.4 
 0.3 mm Hg for the scAAV2.GFP-
FIGURE 2. scAAV2.GFP vector ex-
pression in the anterior segment of
monkey 2. Stable, long-term expres-
sion, monitored serially and noninva-
sively with goniophotography, was
evident in the tissues of the outflow
pathways of the scAAV.GFP-injected
eye. Images were taken with a fun-
dus camera on the indicated postin-
jection days. Bottom right: anterior
chamber angle, OS, shows persistent
GFP expression (A, C white arrows)
at 2.35 years. (A) Image obtained by
custom microscope. (B) Image ob-
tained with a Storz endoscope used
externally with 2.5% hydroxypropyl
methylcellulose as an interface. (C)
Fundus camera image.
IOVS, January 2010, Vol. 51, No. 1 scAAV In Vivo Trabecular Meshwork Transduction 241
injected (treated) eyes in experiment 1 and 11.6 
 0.2 and
11.7 
 0.2 mm Hg, respectively, for experiment 2 (Fig. 5B).
At the end of the experiment, for experiment 1 the IOPs
in each group minus their own baseline were 2.4 
 0.41 mm
Hg for the control group and 2.13 
 0.41 mm Hg for the
treated ones. The IOP between the treated and control
groups was 0.1 
 0.38 mm Hg for experiment 1 (P  0.89)
and 0.3 
 0.55 mm Hg for experiment 2 (P  0.58). The peak
IOP in experiment 1 was 0.37 
 0.33 mm Hg at 27 days
after injection, whereas in experiment 2, it was 0.3 
 0.55 mm
Hg at 75 days (last day of this experiment). There was no
significant difference between the control and treated eyes,
showing that the scAAV2 vector carrying a reporter gene is not
deleterious for the eye pressures of the rat.
The longitudinal IOP (defined as the mean IOP during the
duration of the experiment) was relatively consistent between
control and treated groups with values of 10.42 
 0.17 mm Hg
(control) and 10.34 
 0.20 mm Hg (treated) in experiment 1
and 11.0 
 0.19 mm Hg (control) and 11.0 
 0.17 mm Hg
(treated) in experiment 2.
The mean integral IOP (defined as the cumulative IOP each
animal received during the experiment) of all animals in the
experiment 1 group was 978.1 
 12.5 mm Hg-days for the
controls and 977.9 
 13.0 mm Hg-days for the treated eyes and
824.8 
 14.1 mm Hg-days for the controls and 827.0 
 13.1
mm Hg-days for the treated eyes in the experiment 2 group
(Figs. 5B, 5C). The integral difference (defined as the cumula-
tive IOP exposure of the treated minus the control) was not
significant, with values of 4.9 and 2.2 mm Hg-days for experi-
ments 1 and 2, respectively.
The IOP in monkey 2 averaged 12.7 
 0.55 mm Hg OS
(vehicle-injected) and 13.0 
 0.67 mm Hg OD (virus-injected)
over a span of 208 days after injection. In monkey 1, IOPs were
15.7 
 0.58 mm Hg OD (vehicle-injected) and 15.9 
 0.48 mm
Hg OS (virus-injected) over a span of 781 days after injection.
Effect of scAAV2.GFP on the Transcriptome of
Primary Human Trabecular Meshwork Cells
To gain a first insight on the overall changes induced by
scAAV2.GFP viral infection on trabecular meshwork gene ex-
pression, we infected primary HTM cells with 1  1010 VP
(1400 VP/cell) and used microarray chips to compare their
RNA with that of the uninfected control.
Using the algorithms of the microarray software (Microarray
Suite 5; Affymetrix) to determine present or absent genes in
the chips, we found that overall, the percentage of genes
assigned as present was slightly lower in the scAAV2-infected
cells (39.9%; 8908/22,283) than in the untreated cells (45.5%;
10,137/22,283). The percentage of absent genes was slightly
higher in scAAV2-infected cells, (57.8%; 12,285/22,283) than
in untreated cells (52.4%; 11,684/22,283). In addition, the
subset of genes that were turned on (absent to present) or
turned off (present to absent) by infection of the HTM cells
with scAAV2.GFP was very small, amounting to 110 annotated
nonredundant genes which were turned on (0.49%) and 41
genes that were turned off (0.18%).
Comparison of expression chips of scAAV2-infected versus
untreated cells revealed that the infected cultures had 112
annotated nonredundant genes (0.5%) whose expression was
altered more than twofold. Of this, only 10 genes were upregu-
lated while the remaining 102 were downregulated (see Sup-
plementary Table S1, [INSERT URL]). An overall heat-map of
the genes altered twofold is shown in Figure 6A, which pro-
vides a visual image of the majority of downregulated genes.
Heat maps based on nonredundant gene lists from the GO
biological processes oxidative stress, immune response, and
FIGURE 4. scAAV2.GFP transduction of other anterior segment tissues
in an IC-injected living monkey. Direct fluorescence of wholemounts
and cryosections of the iris (A), and goniophotography and cryosec-
tion of the cornea (B) tissues of monkey 3 at 19 days after injection.
Intense GFP transduction was observed in the posterior face of the iris
as opposed to the anterior face which had little to no GFP. Strong GFP
expression was also observed in the corneal endothelium, especially
when assessed by goniophotography in the living animal. Original
magnification, 200.
FIGURE 3. Histologic assessment of scAAV2.GFP transduction of mon-
key trabecular meshwork. (A) GFP expression examined by direct
fluorescence (top) and immunohistochemistry (bottom) on OCT-em-
bedded, frozen sections from monkey 3 at 19 days after injection. (B)
GFP expression examined by direct fluorescence on frozen sections
from monkey anterior segment organ cultures perfused with 2 to 4 
1010 VP of scAAV2.GFP for 7 days. scAAV2.GFP transduced all cell
layers of the monkey trabecular meshwork as well as the anterior
ciliary muscle. TM, trabecular meshwork; CM, ciliary muscle. Original
magnification: (left) 200; (right), 400.
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extracellular matrix showed minimal, if any change of expres-
sion in the infected cells (Figs. 6B–D).
Because of our interest in specifically determining the effect
of scAAV2.GFP on genes that regulate the immune system, we
performed Venn maps that identified the number of overlap-
ping genes. A Venn map between the list of genes altered
twofold by infection of cells with scAAV2 and the immune
response list yielded five genes, all but one of them downregu-
lated in the scAAV2-infected cells (Figs. 7A, 7B). There were no
overlapping genes between the twofold list and either the
oxidative response or ECM lists (not shown).
Examining the twofold list (Supplementary Table S1, http://
www.iovs.org/cgi/content/full/51/1/236/DC1) for the pres-
ence of genes relevant to trabecular meshwork function and/or
that are part of the trabecular meshwork molecular signature
list (Ref. 41 and our unpublished data, 2004–2008) we found
six genes, all downregulated in the scAAV2-infected cells.
These were secreted frizzled-related protein 1 (SFRP1, FC













scAAV2.GFP 68 Clear 98 d Clear None
Vehicle 28 Clear 98 d Clear None
Monkeys
scAAV2.GFP
1 1 Clear 70 d Clear AC Inflammation at 48 d
2 1 Clear 2.3y* Clear None
3 2 Clear 19 d Clear Trace cells at 6 d
Vehicle 2 Clear 2.3y* Clear None
Clarity and inflammation in monkeys were assessed biomicroscopically.
* Ongoing expression.
FIGURE 5. Effect of a single IC injection of scAAV2.GFP on the IOP of living rats. The rats were injected with equivalent volumes of scAAV2.GFP
(OS; 3–6  109 VP) and vehicle (OD). IOPs were measured, before injection (t  0 days) and at weekly postinjection intervals, in sedated rats using
an induction impact tonometer with a calibrated probe. Results were from two separate, representative experiments (n  8 each) over the course
of 92 and 75 days. (A) Time course of IOPs with tonometer values converted to mm Hg (mean 
 SE). The IOP of the viral-injected eyes at the end
of the experiment was not significantly different from baseline and/or from eyes injected with vehicle. (B) IOP parameters calculated in
scAAV2.GFP- and vehicle-treated eyes. Integral IOPs (cumulative IOP exposure, in mm Hg-days) and peak IOP (maximum IOP elevation during the
experiment) were not significantly different between virus- and vehicle-treated eyes. (C) Graphic representation of the integral IOP of the average
IOPs in experiment 2 in eyes injected with scAAV2.GFP and vehicle. Dark gray area between the viral and vehicle control constitutes the
IOP–integral difference.
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2.3), chemokine (C-X-C) ligand 6 (CXCL6, FC 2.6), matrix
Gla (MGP, FC 3.3), pigment epithelium-derived factor (PEDF,
FC 2.7), fibulin 1 (FBLN1, FC 2.8), osteoglycin (OGN, FC
2.7), and secretogranin (SCG2, FC 2.5). For validation of
the downregulation obtained in the chip, we selected three
genes (MGP, OGN, and SCG2), and measured their normalized
(18S) differential expression by real-time PCR. Results from
triplicate samples showed that the three genes were down-
regulated on scAAV infection: MGP 7.5-fold, OGN 19.7-
fold, and SCG2 5.5-fold. The FCs obtained showed a higher
dynamic range than those in the DNA chip, a phenomenon
known to occur between quantitative PCR and microarrays.53
Examination of the differential expression on the second set
of chips, where the HTM cells had received about one tenth
the number of VP revealed, concordantly, an even lower dif-
ference between scAAV2-infected cells and untreated. The
percentage of genes assigned as present and absent between
the treated and untreated cells was very similar. The percent-
age present in the scAAV2-infected cells was 53.9% (12,012/
22,277), whereas the untreated was 53.7% (11,962/22,277).
The percentage of absent genes was 39.5% (8,793/22,277) for
the scAAV2-infected cells and 40.3% (8,972/22,277) for the
untreated, respectively. In addition, the subset of genes that
were turned on (absent to present) or turned off (present to
absent) by infection of the HTM cells with scAAV2.GFP was
very small, amounting to 16 genes that were turned on (0.07%)
and 10 genes that were turned off (0.04%) in the infected cells.
Comparison of expression chips of scAAV2-infected versus
untreated cells showed that these lower VP-infected cultures
had 17 annotated nonredundant genes (0.08%) with expres-
sion that was altered more than twofold. Of these, 6 genes
were upregulated and the remaining 11 were downregulated.
Three of these genes, FBLN1, OGN, and MGP were downregu-
lated to a lower extent: FC 1.6, 1.9, and 1.1, respectively.
Two of the genes, SFRP1 and CXCL6, were upregulated: FC 1.2
and 1.3, respectively.
Altogether these analyses indicate that at the molecular
level, scAAV2 has a very minor, if any, deleterious effect on the
human trabecular meshwork.
Antibodies to Viral Capsid, Transgene, and
Cellular Immune Response
To assess whether there was a systemic humoral immune
response to the viral capsid or to the transgene, we determined
the levels (as reflected by absorbance at 405 nm) of capsid and
GFP antibodies in the serum of the rats and monkeys by ELISA.
For the capsid, 1  109 scAAV2.GFP VP were bound to 96-well
plates overnight, incubated with serial dilutions of rat and
monkey sera and followed by incubation with an HRP-conju-
gated goat anti-rat or -monkey antibody and developed with an
HRP substrate. For the positive control, a commercial rabbit
anti-AAV2 capsid protein was used as the primary antibody and
a HRP-conjugated goat anti-rabbit as a secondary antibody. For
the transgene, plates were coated with 0.25 g (rats) or 0.50
g (monkeys) of recombinant GFP. Positive control was a
commercial rabbit anti-GFP antibody.
After obtaining preinjection serum, the rats were injected
intracamerallly with 3 to 6  109 VP of scAAV2.GFP as indi-
cated earlier. At 3.5 months after injection, ELISA of pooled
serum from rats of the same treatment group showed a mini-
FIGURE 6. Heat maps of sets of
genes expressed in HTM cells in-
fected with scAAV2.GFP and un-
treated control cells. Primary HTM
cells were infected with scAAV2.GFP
(1000 VP/cell; scAAV2) and har-
vested at 7 days after injection. Un-
treated (UNT) cells grown in parallel
were used as a control. RNA was hy-
bridized to microarray chips and an-
alyzed with gene expression soft-
ware. Expression signals in each chip
were compared to a median value.
Change from the median is visually
represented by a color assignment
(scale at right). Each row represents
the expression of a single gene, and
each column contains the genes se-
lected in each category. (A) Expres-
sion levels of the total number of
genes altered more than twofold in
scAAV2.GFP-infected cells. (B) Ex-
pression levels of oxidative stress
genes generated from the ontology
gene list. (C) Expression levels of im-
mune response genes generated from the ontology gene list. (D) Expression levels of extracellular matrix (ECM) genes generated from the ontology
gene list. Most of the altered genes in scAAV were downregulated from the UNT. Expression of genes in the selected gene lists was barely affected
in the scAAV2.GFP-infected cells.
FIGURE 7. Venn diagrams of genes altered more than twofold and
immune response genes. Each circle represents one gene list category.
Intersections indicate the number of genes that are shared between the
two categories. (A) Genes shared by the lists of altered twofold and
immune response genes. (B) Heat map of the five immune response
genes which were altered more than twofold. Only one immunore-
lated gene (FAS) of the 456 was upregulated, whereas the other four
were downregulated in scAAV2.GFP-infected cells. This adeno-associ-
ated vector had a negligible effect on immune response genes.
244 Buie et al. IOVS, January 2010, Vol. 51, No. 1
mal increase in antibody levels against the viral capsid (P 
0.05; Table 2). There was no increased antibody response to
transgene GFP, and a significant slight decrease was observed
(P  0.02; Table 2). Serum from each of the monkeys was
analyzed separately at 8 months after injection. ELISA of serum
from monkey 1, in which the transgene expression had disap-
peared at 70 days after development of a seemingly unrelated
inflammation, demonstrated that the scAAV intracameral injec-
tion elicited a low, albeit significant, immune response against
the viral capsid (P  0.03; Table 2). In this monkey, there was
a significant increase in antibody titer against the GFP trans-
gene (P  0.000004). ELISA of serum from monkey 2, in which
transgene expression was still noninvasively observed after 2.3
years, resulted in low levels of systemic antibodies against the
viral capsid (P  0.0004) and a significant decrease against the
transgene GFP (P  0.02).
To determine whether the disappearance of reporter ex-
pression (fluorescence) in monkey 1 was due to a cell-medi-
ated immune response against the transgene (GFP), we isolated
PBMCs and tested their proliferative response against GFP in a
primary proliferation assay. At 11 months after injection, blood
was shipped to us overnight at room temperature from the
laboratory of one of the authors (PLK), soon after it was
obtained. PBMCs (22 hours later) were isolated and cultured in
the absence or presence of 10 g/well of rGFP (no good GFP
epitope is known to design an antigenic peptide, and no library
of GFP peptides was available), or stimulated with PMA and
ionomycin (2 and 50 ng/well, respectively). The cells were
incubated for 5 days to allow antigen processing and presen-
tation to T cells. Proliferative response was expressed in
counts per minute, which were used to calculate the SI. The
results showed that monkey 1, which was “silent,” had a
significant T-cell proliferative response against the transgene
GFP (SI, 3.8), whereas no detectable proliferation was ob-
served in monkey 2 (Fig 8).
DISCUSSION
In this study, we showed for the first time that the self-com-
plementary AAV viral vector overrides the lack of AAV trabec-
ular meshwork transduction, not only in cell and human organ
culture36 but in living animals. A single intracameral injection
of the scAAV2 with a CMV-driven GFP in rats and monkeys
resulted in very efficient expression of the transgene in the
trabecular meshwork. In contrast to the delayed transduction
of AAV in the living retina, the expression of the same trans-
gene carried by scAAV in the trabecular meshwork had an early
onset, confirming that the rate-limiting step of AAV transduc-
tion of this eye tissue was the inability of the virus to convert
its ss genome to double stranded.36 The expression of the
transgene in the living animals was long term. In the rat, the
last point measured was 3.5 months, and in monkeys, the
expression of the transgene, as observed by noninvasive go-
nioscopy, is ongoing at 2.35 years after a single intracameral
injection.
As expected with a gene under the control of a ubiquitous
viral promoter, localization of the transgene protein was seen
in anterior segment tissues other than the trabecular mesh-
work by fluorescence and immunohistochemistry. In rats, ex-
pression appeared in the corneal endothelium, both faces of
the iris, and in the ciliary body. In the monkey, expression was
also strong in the ciliary muscle and curiously, very strong in
the posterior face of the iris. This iris posterior face tropism
was not observed in the rat. Although a needle placement
position during the injection could not be excluded, the
marked difference observed in the posterior iris in the monkey
seems more likely to be due to a different tropism of the virus
for the same cell type in the two species. Ongoing experiments
in our laboratory in which additional scAAV serotypes were
used in the rat indicate that while the trabecular meshwork is
transduced efficiently in all pseudotypes tried (2/2, 2/5, and
2/8), different anterior segment patterns of transduction were









Before injection 0.28 
 0.02 0.06 
 0.00
Day 105 0.40 
 0.02 0.04 
 0.00
Positive control 0.77 




Before injection 0.16 
 0.02 0.01 
 0.02
Day 240 0.34 
 0.05 1.30 
 0.00
Monkey 2
Before injection 0.11 
 0.01 0.13 
 0.00
Day 240 0.23 
 0.00 0.05 
 0.03
Positive control 0.89 
 0.01 1.68 
 0.06
Rat serum dilutions: 1:128 (capsid) and 1:40 (GFP); monkey serum
dilutions: 1:80 (capsid) and 1:40 (GFP); positive control dilutions:
1:200 (capsid) and 1:100 (GFP).
FIGURE 8. PBMC proliferative response against the GFP in monkeys. PBMCs derived from the blood
of monkeys 1 and 2 were plated at 2  105 cells/well and cultured without antigen or with GFP at
10 g/well. A stimulation with PMA/ionomycin was used as a positive control. Cells were cultured in
triplicate wells for 5 days, and proliferation was assessed by measurement of [3H]-thymidine incor-
poration. The results are presented as an average counts per minute 
 SE or as a stimulation index
(SI: cpm in stimulated wells/cpm in unstimulated wells). Statistical analysis was performed by
Student’s t-test. *P 	 0.05.
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observed with each of the serotypes. These observations high-
light the importance of tailoring a particular viral vector for the
gene transfer application required.
As when AAV and scAAV vectors transduce the retina of
living animals and humans,54,55 these viruses appear also to be
very safe for the trabecular meshwork. Systematic IOP mea-
surements and evaluations showed no differences between the
eyes injected with the scAAV2.GFP and their contralateral eyes
injected with vehicle. Clinical parameters, including assess-
ment of corneal clarity and inflammation by direct observation
and biomicroscopy, revealed a normal-appearing viral-injected
eye. In the case of the monkeys, normal behavior (interaction
with other monkeys, watching TV) was observed and animals
maintained normal visual acuity (able to easily grasp small
treats). No humoral or cellular-mediated responses were ob-
served in any of the transgene-expressing animals.
The disappearance of transgene expression of monkey 1 at
70 days after injection followed the development of clinical
symptoms suggestive of inflammatory changes in the anterior
chamber. The data suggest that the cause of the loss of scAAV2-
mediated GFP expression in monkey 1 was due to an immune
response to the transgene and not to the scAAV virus. The
PMBC cell proliferation assays showed that this monkey had a
significant T-cell proliferative response against the GFP, indi-
cating that the disappearance of the GFP expression was prob-
ably due to the elimination of GFP-expressing cells by the T
lymphocytes. A recent study reported that AAV.GFP injected
into the liver in monkeys caused an immune response and loss
of expression of the GFP transgene, whereas no response to
the viral capsid was observed. This led the investigators to
conclude that GFP in monkeys is immunogenic.56 Since we
used the same scAAV2.GFP vector for the two separate mon-
keys and obtained distinct durations of expression, it is con-
ceivable that the different GFP immune response observed in
monkey 1was due to a more efficient GFP antigen presentation
by the peripheral blood or local antigen-presenting cells
(APCs), leading to the influx of T cells to the trabecular mesh-
work. The differences in the genetic background between the
two animals could have contributed to a different efficiency of
antigen presentation, as reflected by different immunogenicity
of GFP in two animals.
Finally, comparison arrays between scAAV2-infected and
vehicle-treated primary HTM cells showed a minimal effect of
the virus on the modulation of the cells’ gene expression. The
results obtained do not significantly differ from those that have
been published by our group and others on the effect of AAV
viruses in the cells’ transcriptome.36,57 Only 0.5% of the 22,283
genes of the array were altered more than twofold and of
those, most were downregulated. Overall, the altered expres-
sion was low to moderate, with only 10 genes upregulated
more than twofold and the highest altered gene having a value
of less than sixfold (5.7-fold; Supplementary Table S1, [IN-
SERT URL]). No genes reported to be relevant in the trabecular
meshwork40,41,58 were on the list of twofold upregulated
genes. However, the downregulated gene list contained a few
genes that have been shown to be altered under known insults
to the trabecular meshwork tissue, such as elevated IOP, dexa-
methasone (DEX), and transforming growth factor-2
(TGF2).59–61 Thus, SFRP1 is a Wnt pathway antagonist gene
which is upregulated in response to elevated IOP62 and whose
overexpression induced high IOP in mice.10 The cytokine
CXCL6 and MGP, an inhibitor of calcification, were found
among the genes most altered by high IOP62; in addition, MGP
was downregulated in glaucomatous tissues and upregulated
by TGF2.63 PEDF, a neuroprotector; OGN, a calcification-
related protein; and SCG2, a neuropeptide precursor involved
in secretion modulation, were upregulated by high IOP62; in
addition PEDF was specifically induced by DEX,41,64 OGN was
induced by TGF265 and found in a glaucoma proteomic anal-
ysis,66 and SCG2 was reduced by DEX.41,67 Downregulation of
SCG2 by the AAV2 virus had been observed in the trabecular
meshwork cells.36 FBLN1, a secreted glycoprotein that be-
comes incorporated into fibrillar ECM on binding to calcium, is
also altered by DEX.41 Only five immune-related genes were
found to be present in the list of twofold altered genes, an
indication of the low immunogenicity of this vector. Of the
five, FAS, a member of the tumor necrosis factor superfamily
was upregulated, whereas the two cytokines CXCL6 and
CXCL12 were among the most downregulated. Modulation of
these genes by scAAV2 infection could have some beneficial or
detrimental effect in the trabecular meshwork and should be
taken into account when using these vectors.
In summary, the results of this study indicate that the scAAV
viral vectors, as well as the original AAV vectors, are very safe
for gene therapy in the eye of a living animal. In addition, and
in contrast to AAV, the scAAV vectors are able to transduce the
trabecular meshwork in vivo. This transduction is long term
and has a very rapid onset. The intensity of the GFP expression
could be observed at 4 days after injection and lasted at least
3.5 months in rats (assessed by histology) and is ongoing after
2.3 years in a monkey (as observed by noninvasive goniopho-
tography). The scAAV vectors proved to maintain all the safe
clinical characteristics of the AAV vectors, which to date are
the preferred gene therapy vectors for retinal diseases.54 Because
of the need in glaucoma to develop therapies tailored to restore
the function of the trabecular meshwork, the scAAV vectors
emerge as strong candidates for the treatment of this disease by
gene therapy. Several potentially therapeutic genes have been
identified by us and others in recent years.10,40,41,68,69 This, to-
gether with a complete evaluation of different scAAV serotypes
(in process), will further contribute to a better targeted transgene
delivery and to the goal of modulating the function of the outflow
pathway by safe gene transfer to the trabecular meshwork.
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